Denali Therapeutics
Market Cap
US$1.7b
Last Updated
2019/12/11 01:15 UTC
Data Sources
Company Financials +
Executive Summary
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -11.2% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with concerning outlook.
Share Price & News
How has Denali Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DNLI has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-0.08%
DNLI
0.1%
US Biotechs
1.1%
US Market
1 Year Return
-12.6%
DNLI
14.7%
US Biotechs
17.8%
US Market
Return vs Industry: DNLI underperformed the US Biotechs industry which returned 14.7% over the past year.
Return vs Market: DNLI underperformed the US Market which returned 17.8% over the past year.
Shareholder returns
| DNLI | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.08% | 0.1% | 1.1% |
| 30 Day | 22.2% | 9.0% | 1.4% |
| 90 Day | -4.8% | 15.2% | 3.9% |
| 1 Year | -12.6%-12.6% | 15.7%14.7% | 20.3%17.8% |
| 3 Year | n/a | 28.4%24.3% | 44.8%35.4% |
| 5 Year | n/a | 10.2%5.0% | 71.3%52.4% |
Price Volatility Vs. Market
How volatile is Denali Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Denali Therapeutics Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know8 months ago | Simply Wall St
Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?1 year ago | Simply Wall St
Is Denali Therapeutics Inc's (NASDAQ:DNLI) Balance Sheet Strong Enough To Weather A Storm?Valuation
Is Denali Therapeutics undervalued compared to its fair value and its price relative to the market?
3.97x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DNLI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DNLI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DNLI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: DNLI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DNLI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DNLI is overvalued based on its PB Ratio (4x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Denali Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
-11.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNLI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNLI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNLI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNLI's revenue (15.4% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: DNLI's revenue (15.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DNLI is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Denali Therapeutics performed over the past 5 years?
-3.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DNLI is currently unprofitable.
Growing Profit Margin: DNLI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DNLI is unprofitable, and losses have increased over the past 5 years at a rate of -3.1% per year.
Accelerating Growth: Unable to compare DNLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: DNLI has a negative Return on Equity (-15.07%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Denali Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: DNLI's short term assets ($494.4M) exceed its short term liabilities ($46.7M).
Long Term Liabilities: DNLI's short term assets ($494.4M) exceed its long term liabilities ($118.1M).
Debt to Equity History and Analysis
Debt Level: DNLI is debt free.
Reducing Debt: DNLI has not had any debt for past 5 years.
Balance Sheet
Inventory Level: DNLI has a low level of unsold assets or inventory.
Debt Coverage by Assets: DNLI's debt is not covered by short term assets (assets are -3.4788688640321E+16x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DNLI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DNLI has sufficient cash runway for 1.872195 years if free cash flow continues to grow at historical rates of 53.6% each year.
Next Steps
Dividend
What is Denali Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate DNLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate DNLI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DNLI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DNLI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DNLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Denali Therapeutics's salary, the management and board of directors tenure and is there insider trading?
2.8yrs
Average management tenure
CEO
Ryan Watts (43yo)
4.3yrs
Tenure
US$5,983,923
Compensation
Dr. Ryan J. Watts, Ph.D. is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since August 2015. Dr. Watts has been a Director of Denali Therapeutics Inc. si ...
CEO Compensation Analysis
Compensation vs Market: Ryan's total compensation ($USD5.98M) is above average for companies of similar size in the US market ($USD3.87M).
Compensation vs Earnings: Ryan's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
2.8yrs
Average Tenure
46yo
Average Age
Experienced Management: DNLI's management team is considered experienced (2.8 years average tenure).
Board Age and Tenure
4.6yrs
Average Tenure
59yo
Average Age
Experienced Board: DNLI's board of directors are considered experienced (4.6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24%.
Management Team
Marc Tessier-Lavigne (59yo)
Co-Founder
- Tenure: 0yrs
- Compensation: US$405.13k
Steve Krognes (51yo)
CFO & Treasurer
- Tenure: 4.2yrs
- Compensation: US$4.00m
Ryan Watts (43yo)
Co-Founder
- Tenure: 4.3yrs
- Compensation: US$5.98m
Alex Schuth (46yo)
Co-Founder
- Tenure: 0yrs
- Compensation: US$3.90m
Carole Ho (46yo)
Chief Medical Officer & Head of Development
- Tenure: 4.5yrs
- Compensation: US$3.94m
Dana Andersen
Chief Technical and Manufacturing Officer
- Tenure: 1.3yrs
Cindy Dunkle
Chief People Officer
- Tenure: 0yrs
Joe Lewcock
Head of Biology Discovery
- Tenure: 0yrs
Zach Sweeney
Chief Scientific Officer
- Tenure: 0.08yrs
Chris Walsh
Vice President of Legal
- Tenure: 0.9yrs
Board Members
Bob Nelsen (57yo)
Independent Director
- Tenure: 4.6yrs
- Compensation: US$383.88k
Vicki Sato (70yo)
Independent Chairperson
- Tenure: 3.3yrs
- Compensation: US$428.13k
Jay Flatley (66yo)
Independent Director
- Tenure: 4.7yrs
- Compensation: US$404.17k
Marc Tessier-Lavigne (59yo)
Co-Founder
- Tenure: 0yrs
- Compensation: US$405.13k
David Schenkein (62yo)
Independent Director
- Tenure: 4.7yrs
- Compensation: US$404.13k
Peter Klein (57yo)
Independent Director
- Tenure: 1.8yrs
- Compensation: US$643.85k
Scott Biller (63yo)
Member of Scientific Advisory Board
- Tenure: 0yrs
Doug Cole (59yo)
Independent Director
- Tenure: 4.6yrs
- Compensation: US$402.63k
Ryan Watts (43yo)
Co-Founder
- Tenure: 4.3yrs
- Compensation: US$5.98m
Alison Goate
Member of Scientific Advisory Board
- Tenure: 0yrs
Company Information
Denali Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Denali Therapeutics Inc.
- Ticker: DNLI
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.742b
- Shares outstanding: 96.03m
- Website: https://www.denalitherapeutics.com
Number of Employees
Location
- Denali Therapeutics Inc.
- 161 Oyster Point Boulevard
- 2nd Floor
- South San Francisco
- California
- 94080
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 4DN | MUN (Boerse Muenchen) | Yes | Common Stock | DE | EUR | Dec 2017 |
| DNLI | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Dec 2017 |
| 4DN | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Dec 2017 |
Biography
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LR ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/11 01:15 |
| End of Day Share Price | 2019/12/10 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.